GPCR

Structure Therapeutics Stock Analysis

AI Rating

Low
  • Quality2/10
  • Growth↓ 0/10
  • Value↑ 6/10
Structure Therapeutics sales and earnings growth
GPCR Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -1.15%
  • FCF Y/Y↓ -16.88%
Structure Therapeutics gross and profit margin trends
GPCR Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -33.76%
Structure Therapeutics net debt vs free cash flow
GPCR Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Structure Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks